annotations:
  0:
    partial: false
    structured:
    - object: CHD Death
    - object: Non-fatal MI
    - object: Ischemic Stroke
  1:
    partial: true
    structured:
    - object: Acute Febrile Illness
      time: 7-day Period Following the Onset
      measure: Number
  2:
    partial: true
    structured:
    - object: Alanine Aminotransferase (ALT)
      measure: Percentage of Participants
      range: More Than 1.5 Times Upper Limit of Normal
      range_norm: Above Normal
    - object: Aspartate Aminotransferase (AST)
      measure: Percentage of Participants
      range: More Than 1.5 Times Upper Limit of Normal
      range_norm: Above Normal
  3:
    partial: false
    structured:
    - object: CD4/CD8 Cell Counts
      measure: Mean Change From Baseline
  4:
    partial: true
    structured:
    - object: Dasatinib
      measure: Number of Subjects
      measure_norm: Number of Participants
  5:
    partial: true
    structured:
    - object: Costs for Referrals
  6:
    partial: true
    structured:
    - object: Duration of Solicited Local Symptoms
      time: After Vaccination
  7:
    partial: false
    structured:
    - object: Partial Onset Seizures (Type I)
      measure: Percentage of Responder Subjects
      time: Up-titration Period
  8:
    partial: true
    structured:
    - object: Leibowitz Social Anxiety Scale (LSAS) Total Score
      measure: Change From Baseline
      time: 1-Month
  9:
    partial: true
    structured:
    - object: Area Under the Plasma Concentration-time Curve
  10:
    partial: false
    structured:
    - object: Transitional Dyspnea Index (TDI) Score
  11:
    partial: true
    structured:
    - object: Survival
      time: Step 1
  12:
    partial: true
    structured:
    - object: Equivalence of Seroprotection Against Poliovirus
      time: After Vaccination
  13:
    partial: true
    structured:
    - object: Vital Sign Parameter of Heart Rate
      time: During the Double-blind Treatment Period
      measure: Change From Baseline
  14:
    partial: true
    structured:
    - object: Safety
      time: Who Have Recently Quit Smoking
    - object: Tolerability
      time: Who Have Recently Quit Smoking
  15:
    partial: false
    structured:
    - object: Anxiety Symptoms
      measure: Change
  16:
    partial: false
    structured:
    - object: Lipids
  17:
    partial: true
    structured:
    - object: Invasive Ventilator-Free Survival
      measure: Number of Participants
  18:
    partial: true
    structured:
    - object: Social Function Domain Score
      time: Baseline
    - object: Social Function Domain Score
      time: Weeks 6
    - object: Social Function Domain Score
      time: Weeks 14
  19:
    partial: true
    structured:
    - object: Achieved Platelet Engraftment
      time: By Day 12 But No Later Than Day 21
      measure: Number of Transplants
  20:
    partial: false
    structured:
    - object: Subjective Sleep Onset Latency
      measure: Change From Baseline
      time: Month 6
  21:
    partial: false
    structured:
    - object: Operator Satisfaction
      specifier: With Manual Device and Powered Device
  22:
    partial: false
    structured:
    - object: Trough FEV1 Response
      time: Week 6
  23:
    partial: false
    structured:
    - object: Blood Eosinophils (Cells/uL)
      time: Week 52
      measure: Mean Change from Baseline
  24:
    partial: true
    structured:
    - object: Grade 3-4 Hematology Abnormalities
      specifier: Occurring in >=5% Participants
      measure: Number of Participants
  25:
    partial: false
    structured:
    - object: Plasma Concentration
      specifier: Cycle 1/Day 25
      measure: Maximum Observed
  26:
    partial: false
    structured:
    - object: Diabetes
      measure: Quantitative Change
  27:
    partial: false
    structured:
    - object: Serum Iron
  28:
    partial: true
    structured:
    - object: Number of Glucose-Lowering Treatments
      time: Weeks 12 and 24
      measure: Absolute Change From Baseline
  29:
    partial: false
    structured:
    - object: Occurrence of Treatment-emergent Adverse Events
    - object: Severity of Treatment-emergent Adverse Events
  30:
    partial: false
    structured:
    - object: Best Overall Response Rate
  31:
    partial: false
    structured:
    - object: Difference Between Groups (HBO Minus HBA)
      measure: Change in Scores
      specifier: 'Pediatric Evaluation of Disability Inventory (PEDI) Functional Skills:
        Social Function'
      time: Post-treatment Minus Pre-treatment
  32:
    partial: false
    structured:
    - object: Clinical Global Impression Improvement Score
      measure: Percentage of Participants
      time: Week 26
  33:
    partial: false
    structured:
    - object: Descend Steps
      time: Pre-Intervention
  34:
    partial: false
    structured:
    - object: Maximum Severity
      measure: Number of Participants
      specifier: Each stage
  35:
    partial: true
    structured:
    - object: Difference in VAS Pain Scale Scores
      measure: Proportion of the Subjects
      specifier: Within the Subject (VAS of the Control Medical Device - VAS of the
        Test Medical Device)
      time: Immediately After Treatment
  36:
    partial: false
    structured:
    - object: Adinopectin
      measure: Adjusted Mean Change
      time: Week 52
  37:
    partial: true
    structured:
    - object: HAQ-DI
      measure: Change From Baseline
      time: Month 6
  38:
    partial: true
    structured:
    - object: Adverse Events
      measure: Number
      time: Week 0-52
  39:
    partial: false
    structured:
    - object: Meeting the Criteria of the American College of Rheumatology for 20%
        Improvement
      measure: Percentage of Participants
  40:
    partial: false
    structured:
    - object: TEAEs
      measure: Number of Participants
    - object: Grade >= 3 TEAEs
      measure: Number of Participants
    - object: Serious TEAEs
      measure: Number of Participants
    - object: Treatment Related TEAEs
      measure: Number of Participants
  41:
    partial: false
    structured:
    - object: Buccal Cells Demonstrating a Decline in Cyclin D1
      measure: Number of Patients
  42:
    partial: false
    structured:
    - object: Self-Reported Spray Doses
      measure: Maximum Total Daily Number
      time: Week 17
  43:
    partial: false
    structured:
    - object: Infant Sleep Quantity
      measure: Change
  44:
    partial: false
    structured:
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 3 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 6 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 9 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 12 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 18 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 24 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 30 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 36 Months
    - object: Emotional Well-Being (EWB) Subscale Score
      measure: Change From Baseline
      time: 48 Months
  45:
    partial: false
    structured:
    - object: Adverse Events
      measure: Percentage of Participants
      time: Within 1 Month After Dose 2
  46:
    partial: false
    structured:
    - object: PIK3CA Mutation
      measure: Number of Participants
      time: Baseline
  47:
    partial: true
    structured:
    - object: eSAGE Score
  48:
    partial: true
    structured:
    - object: Visual Analog Pain Scale
  49:
    partial: true
    structured:
    - object: Severity Total Score
      time: Weeks 0
    - object: Severity Total Score
      time: Weeks 2
    - object: Severity Total Score
      time: Weeks 4
    - object: Severity Total Score
      time: Weeks 5
    - object: Severity Total Score
      time: Weeks 6
    - object: Severity Total Score
      time: Weeks 8
    - object: Severity Total Score
      time: Weeks 12
    - object: Severity Total Score
      time: Weeks 16
    - object: Severity Total Score
      time: Weeks 20
    - object: Severity Total Score
      time: Weeks 24
    - object: Severity Total Score
      time: Weeks 28
    - object: Severity Total Score
      time: Weeks 32
    - object: Severity Total Score
      time: Weeks 36
    - object: Severity Total Score
      time: Weeks 40
    - object: Severity Total Score
      time: Weeks 44
    - object: Severity Total Score
      time: Weeks 48
    - object: Severity Total Score
      time: Weeks 52
  50:
    partial: false
    structured:
    - object: Patient Satisfaction
      time: 3 Months
  51:
    partial: false
    structured:
    - object: Corneal Staining Score
      measure: Mean
  52:
    partial: true
    structured:
    - object: ELISA Antibody
      measure: Percentage of Subjects
      range: Rise
  53:
    partial: false
    structured:
    - object: Elvitegravir Concentration
      measure: Change
      specifier: In Penile Secretions
  54:
    partial: false
    structured:
    - object: PTSD Symptoms
      measure: Change
      specifier: As Measured by the PCL
  55:
    partial: true
    structured:
    - object: Dengue Viremia
      measure: Number of Cases
      time: Following Vaccination
    - object: Dengue Viremia
      measure: Number of Cases
      time: Following Placebo
  56:
    partial: false
    structured:
    - object: Adverse Events
      measure: Number of Participants
      specifier: High-Grade (Grade 3-4) Immune Mediated
  57:
    partial: false
    structured:
    - object: Pain Intensity and TBW
      measure: Correlation between Change
      time: 15 Minutes Post-treatment
  58:
    partial: true
    structured:
    - object: Area Under the Plasma Concentration-time Curve
      time: From time 0
  59:
    partial: true
    structured:
    - object: MSIS-29 Psychological Score
      measure: Change From Baseline
      time: Months 3
    - object: MSIS-29 Psychological Score
      measure: Change From Baseline
      time: Months 6
    - object: MSIS-29 Psychological Score
      measure: Change From Baseline
      time: Months 9
    - object: MSIS-29 Psychological Score
      measure: Change From Baseline
      time: Months 12
  60:
    partial: false
    structured:
    - object: Implant Insertion Time
      unit: Seconds
  61:
    partial: true
    structured:
    - object: Confirmed Best Objective Response
      measure: Percentage of Participants
      specifier: Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
  62:
    partial: true
    structured:
    - object: Treatment-emergent Resistance-associated Substitutions
      measure: Percentage of Participants
      time: Week 49
      specifier: From the Pooled Treatment Group
  63:
    partial: false
    structured:
    - object: Follow-up Visits
      measure: Change From Baseline
      specifier: in Exercise Tolerance
  64:
    partial: true
    structured:
    - object: Associations Between Polymorphisms
      specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically
    - object: Efficacy
      specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically
    - object: Toxicities
      specifier: Within CYPs 2C8, 3A4, 3A5 and/or the UGT1A1 Collectively or Monogenically
  65:
    partial: false
    structured:
    - object: Patients Treated With Pentamidine
      measure: Response Rate
  66:
    partial: false
    structured:
    - object: Area Under Curve
      specifier: Over a Uniform Dosing Interval Tau
      time: at Steady State
  67:
    partial: false
    structured:
    - object: Heartburn-Free 24-hour Days
      measure: Percentage
  68:
    partial: true
    structured:
    - object: Triiodothyronine
      measure: Change From Baseline
  69:
    partial: false
    structured:
    - object: Worst Case Body Temperature Values
      measure: Number of Participants
      specifier: of PCI
  70:
    partial: true
    structured:
    - object: Systolic Blood Pressure
      range: <90 mmHg
      time: Within 30 minutes
      measure: Percentage of Patients
  71:
    partial: true
    structured:
    - object: Abnormal Glycosylated Hemoglobin Value
      measure: Number of Participants
  72:
    partial: false
    structured:
    - object: REGN10933 Concentration
      specifier: in Serum
  73:
    partial: false
    structured:
    - object: Surgical Site
      measure: Occurrence Rate
  74:
    partial: false
    structured:
    - object: Forced Vital Capacity
      measure: Annual Rate of Decline
  75:
    partial: false
    structured:
    - object: Maternal Morbidity
  76:
    partial: false
    structured:
    - object: CD22 Expression Levels
      specifier: From Peripheral Blood by Best Response
  77:
    partial: true
    structured:
    - object: Basophils
      measure: Change
  78:
    partial: false
    structured:
    - object: Rescue Medication
      specifier: Observed Data
      time: Week 64
      measure: Number of Participants
  79:
    partial: false
    structured:
    - object: Pathogen
      specifier: Identified by the Karius Test and Standard Culture Methods
      time: at Time Point IP2
      measure: Number of Participants
  80:
    partial: true
    structured:
    - object: Time to Need for Antibiotics
      specifier: Inhaled Antipseudomonal for Respiratory Event
    - object: Time to Need for Antibiotics
      specifier: IV Antipseudomonal for Respiratory Event
  81:
    partial: false
    structured:
    - object: Incidence of Cervical Intraepithelial Neoplasia
      specifier: Associated With High-risk HPV Types Other Than 16/18 in Participants
        >26 Years of Age
  82:
    partial: false
    structured:
    - object: SBP
      measure: Combined Mean Change
      time: from Baseline to Week 6
      specifier: Mean by Patient
    - object: SBP
      measure: Combined Mean Change
      time: from Baseline to Week 8
      specifier: Mean by Patient
  83:
    partial: false
    structured:
    - object: Safety
      specifier: Peptide Vaccines
  84:
    partial: false
    structured:
    - object: Low Density Lipoprotein Cholesterol
      measure: Percent Change From Baseline
      time: Week 12
  85:
    partial: true
    structured:
    - object: Hot Flash Related Daily Interference Scale
  86:
    partial: false
    structured:
    - object: Mean Worse Eye Intraocular Pressure
      specifier: Analyzed by Mixed-Effect Model for Repeated Measure
      measure: Change From Baseline
  87:
    partial: false
    structured:
    - object: Cartilage Thickness of the Total Tibiofemoral Compartment (tTFC)
      specifier: the Target Knee by qMRI
      time: Week 52
      measure: Change From Baseline
  88:
    partial: true
    structured:
    - object: Brief Fatigue Inventory (BFI) Worst Fatigue Score
      measure: Change From Baseline
  89:
    partial: false
    structured:
    - object: Ketamine
      measure: AUC
  90:
    partial: false
    structured:
    - object: Recurrent Disease
      measure: Percentage of Participants
  91:
    partial: false
    structured:
    - object: Progression-free Survival
      time: 36 Months
      specifier: Among Patients Who Are PET Positive After Induction Treatment
  92:
    partial: false
    structured:
    - object: Health Assessment Questionnaire-Disability Index Changes
      time: From Week 24 at Week 48
      specifier: in Patients Treated Continuously With GP2017 and in Patients Treated
        With GP2017 After Switch From Humira
  93:
    partial: false
    structured:
    - object: Snack Added Sugars Purchased
      time: Week 1
  94:
    partial: false
    structured:
    - object: Overall Survival
      measure: Number of Participants
  95:
    partial: false
    structured:
    - object: Knee Injury and Osteoarthritis Outcome Score Pain sub scores
      measure: Change From Baseline
    - object: Knee Injury and Osteoarthritis Outcome Score Activities of Daily Living
      measure: Change From Baseline
  96:
    partial: false
    structured:
    - object: Suppression of Plasma Renin Activity
      measure: Magnitude
      specifier: From Low Sodium to High Sodium Diets
  97:
    partial: false
    structured:
    - object: Terminal Half-life
      specifier: Metabolite PR-389/M14
  98:
    partial: false
    structured:
    - object: Trichiasis Severity Levels
      time: 3-6 Months
      measure: Number of Eyelids
  99:
    partial: true
    structured:
    - object: Remission Rate
      specifier: Retrospective-Modified Overt Aggression Scale (R-MOAS)
  100:
    partial: false
    structured:
    - object: adverse effects
      measure: number of patients
  101:
    partial: true
    structured:
    - object: peak expiratory flow
      time: last week of the 8-week treatment period
      measure: mean
      specifier: pre-dose (and pre-rescue), as assessed via asthma monitor (am2+)
  102:
    partial: true
    structured:
    - object: disease control
      measure: percentage of participants
      specifier: according to recist version 1.1 in participants with low ercc-1 levels
  103:
    partial: false
    structured:
    - object: bcva
      measure: change
      specifier: in non-treated contralateral eye
  104:
    partial: true
    structured:
    - object: forced expiratory volume (fev1)
      specifier: in one second
      measure: mean change from baseline
      time: 2 hours post-dose
  105:
    partial: true
    structured:
    - object: asthma symptom score
      time: night time
  106:
    partial: false
    structured:
    - object: enclomiphene pharmacokinetic parameters
      time: week 6 - tmax
  107:
    partial: false
    structured:
    - object: observed serum
      measure: maximum concentration (cmax)
      specifier: after administration of tba7371
  108:
    partial: false
    structured:
    - object: subject compliance with iti treatment regimen
      specifier: with iti treatment regimen
  109:
    partial: false
    structured:
    - object: phes
      time: week 26
      specifier: from pre-vancomycin
  110:
    partial: false
    structured:
    - object: pba of napba
      measure: cmax
      specifier: in plasma
    - object: hpn-100
      measure: cmax
      specifier: in plasma
  111:
    partial: true
    structured:
    - measure: number of patients
      object: adverse events
  112:
    partial: false
    structured:
    - object: Quality of life
      measure: change in mean
      specifier: measured with the veines qol/sym questionnaire
  113:
    partial: false
    structured:
    - object: promis measures-anger
  114:
    partial: false
    structured:
    - object: auct
      specifier: dose-normalized
      time: day 1
  115:
    partial: false
    structured:
    - object: patient satisfaction
      specifier: deflation mechanism
  116:
    partial: false
    structured:
    - object: preferred brand smoke intake
      specifier: co
  117:
    partial: false
    structured:
    - object: severe cae
      specifier: when albuterol use increased
      time: prior to the peak
      measure: Number of days
  118:
    partial: false
    structured:
    - object: pain relief
      time: at 2 hours
      specifier: during the third migraine attack period
  119:
    partial: true
    structured:
    - object: attachment level
      specifier: using a williams periodontal probe
  120:
    partial: false
    structured:
    - object: cognitive function
      specifier: hopkins verbal learning test
      measure: total recall score
  121:
    partial: false
    structured:
    - object: adenoma detection rate
      specifier: colon ascendens
  122:
    partial: false
    structured:
    - object: area under the curve
      specifier: auc3.9-ig
      range: "ig \u22643.9 mmol/l [70 mg/dl]"
  123:
    partial: true
    structured:
    - object: significant laboratory values
      measure: number of participants
  124:
    partial: false
    structured:
    - object: visual acuity
      range: at least 0.30 logmar
      specifier: gaining in binocular distance-corrected (without near correction)
      measure: percentage of participants
      time: from baseline at month 3
  125:
    partial: true
    structured:
    - object: palatability
      specifier: trametinib oral solution
  126:
    partial: false
    structured:
    - object: patients with a stillbirth
      specifier: after rpl
  127:
    partial: false
    structured:
    - object: insulin dose
      specifier: total bolus
      unit: units/kg/day
  128:
    partial: false
    structured:
    - object: Antiretroviral resistance
      specifier: to gw873140 400 mg bid and other antiretroviral drugs
      measure: Number of participants
  129:
    partial: false
    structured:
    - object: Adverse effect
      measure: Number of participants
  130:
    partial: true
    structured:
    - measure: change in mean
      object: self-confidence score
  131:
    partial: true
    structured:
    - measure: change from baseline
      object: vitality
      specifier: short form 36-item health survey domain
      time: at week 34
  132:
    partial: false
    structured:
    - object: pain
      specifier: with needling
  133:
    partial: true
    structured:
    - object: concentration of rivaroxaban
      specifier: in plasma
      time: day 1
  134:
    partial: false
    structured:
    - object: plasma concentration time profiles
      specifier: by treatment group
      time: in expansion phase
  135:
    partial: true
    structured:
    - object: physically active
      measure: number of participants
    - object: not physically active
      measure: number of participants
  136:
    partial: false
    structured:
    - object: absolute fbf
      measure: change
      specifier: in response to l-nmma in participants treated with darbepoetin alfa
      time: day 42 vs day 1
  137:
    partial: false
    structured:
    - object: pef
      measure: change from baseline
      specifier: averaged over the 12-week treatment period
      time: in daily morning
  138:
    partial: true
    structured:
    - object: score of facit-fatigue scale
  139:
    partial: false
    structured:
    - object: bowel length
  140:
    partial: false
    structured:
    - object: evr
      measure: number of participants
      specifier: by selected chronic hcv genotypes (stage 1)
  141:
    partial: false
    structured:
    - measure: number of participants
      object: dose-limiting toxicities (dlts)
      time: in first 2 cycles of portion a
  142:
    partial: false
    structured:
    - object: medically significant conditions (mscs)
      measure: number of subjects
      time: from day 0 up to month 7
  143:
    partial: false
    structured:
    - object: resolution of dactylitis
      measure: percentage of participants
      specifier: among participants with dactylitis at baseline
      time: weeks 52
    - object: resolution of dactylitis
      measure: percentage of participants
      specifier: among participants with dactylitis at baseline
      time: weeks 76
    - object: resolution of dactylitis
      measure: percentage of participants
      specifier: among participants with dactylitis at baseline
      time: weeks 100
  144:
    partial: false
    structured:
    - object: depressive symptoms
      measure: level
      specifier: per edinburgh postnatal depression scale (epds)
  145:
    partial: false
    structured:
    - object: event free survival (efs)
      measure: median
  146:
    partial: false
    structured:
    - measure: change
      object: smpg profiles per time point
      time: from baseline to month 6
      specifier: in 8--point
  147:
    partial: false
    structured:
    - object: hematology laboratory parameters
      specifier: worst changes
      measure: number of participants
      time: during the in the placebo controlled period
  148:
    partial: true
    structured:
    - object: pcl-5 score
      specifier: ptsd symptoms
      measure: change
  149:
    partial: false
    structured:
    - measure: change from baseline
      object: concentration of gag
      specifier: in urine
      time: at week 48
  150:
    partial: false
    structured:
    - object: toxicity
      specifier: assessed using national cancer institute (nci) common terminology
        criteria for adverse events (ctcae) version 5.0 (v5)
  151:
    partial: false
    structured:
    - object: insulin doses
      measure: average daily
  152:
    partial: false
    structured:
    - object: objective response - phase 1
      measure: percentage of participants
  153:
    partial: false
    structured:
    - object: renal deterioration
      measure: percentage of participants
      time: at any post baseline visit through day 14
  154:
    partial: false
    structured:
    - object: quality of life
      specifier: measured by the breast-q questionnaire
  155:
    partial: true
    structured:
    - object: minor response rate
  156:
    partial: false
    structured:
    - object: evaluation of biomarkers
  157:
    partial: false
    structured:
    - object: reduction in tumour volume
      measure: number of patients
      time: from baseline volume (visit 1) to week 12 (visit 3)
      range: at least a 20%
    - object: reduction in tumour volume
      measure: number of patients
      time: from baseline volume (visit 1) to week 24 (visit 4)
      range: at least a 20%
  158:
    partial: false
    structured:
    - object: influenza vaccine coverage
      specifier: for all household contacts of newborns
      measure: percent
  159:
    partial: true
    structured:
    - object: incidence
      specifier: of new tec
    - object: incidence
      specifier: of major bleeding
  160:
    partial: false
    structured:
    - object: pulmonary exacerbation
      measure: time to first
      time: over the 26-week treatment period
  161:
    partial: false
    structured:
    - object: received concomitant non-cancer therapy
      measure: percentage of participants
  162:
    partial: false
    structured:
    - object: mean pain score
      measure: change from baseline
      time: daily
      specifier: pain rating scale (dprs)
  163:
    partial: false
    structured:
    - object: neck pain
      measure: average level
  164:
    partial: false
    structured:
    - measure: change from baseline
      object: toxin immunoglobulin g levels
      specifier: among seropositive participants who received tdap to those who received
        td
  165:
    partial: false
    structured:
    - object: estimated post-bronchodilator slow vital capacity (svc)
      time: at month 48
  166:
    partial: false
    structured:
    - object: terminal half-life (t1/2)
      specifier: of danirixin for part 2
  167:
    partial: false
    structured:
    - measure: number of patients
      object: transmitted light intensity
      specifier: to gastric wall thickness
  168:
    partial: false
    structured:
    - object: lens fit
      measure: horizontal centration
      specifier: hema-copolymer
    - object: lens fit
      measure: horizontal centration
      specifier: etafilcon a
  169:
    partial: true
    structured:
    - object: objective response rate (or)
      specifier: where or=cr+pr
  170:
    partial: false
    structured:
    - object: ambulation
      measure: time of first
  171:
    partial: true
    structured:
    - object: terminal phase half-life (t1/2)
      specifier: gsk3358699
  172:
    partial: false
    structured:
    - object: nbs
      time: at week 40
      measure: change from baseline
  173:
    partial: false
    structured:
    - object: efficacy
      specifier: all-cause mortality
  174:
    partial: false
    structured:
    - object: spga
      time: from baseline at week 24
      specifier: by baseline bsa involvement subgroups
      range: at least a 2 grade improvement
      measure: percentage of participants
  175:
    partial: false
    structured:
    - object: experienced adverse events (aes)
      measure: number of participants
    - object: serious adverse events
      measure: number of participants
    - object: deaths
      measure: number of participants
  176:
    partial: false
    structured:
    - object: success rate
  177:
    partial: true
    structured:
    - object: used concomitant medications and rescue medications
      measure: number of participants
  178:
    partial: false
    structured:
    - measure: number of participants
      object: hospitalization for heart failure (hhf)
      time: until 30 days after initial hospital discharge
  179:
    partial: false
    structured:
    - object: vital signs data meeting categorical criteria
      specifier: absolute values
      measure: number of participants
  180:
    partial: false
    structured:
    - object: percent radioactivity recovered
      specifier: for each metabolite in duodenal bile
      time: "following a single dose of [14c]-gsk1278863 50 \xB5g iv infusion"
  181:
    partial: false
    structured:
    - object: days
      specifier: with < 8 micturitions
      measure: number
      time: weeks 4
    - object: days
      specifier: with < 8 micturitions
      measure: number
      time: weeks 8
    - object: days
      specifier: with < 8 micturitions
      measure: number
      time: weeks 12
    - object: days
      specifier: with < 8 micturitions
      measure: number
      time: eot
  182:
    partial: false
    structured:
    - object: methotrexate clearance
      specifier: in induction cycle 2
  183:
    partial: false
    structured:
    - measure: percentage of participants
      object: psoriasis area severity index (pasi) score (pasi 100)
      specifier: achieving 100% improvement
      time: at week 16
  184:
    partial: false
    structured:
    - object: "montgomery \xE5sberg depression rating scale (madrs) total score"
      specifier: through phase 3
      measure: mean baseline
    - object: "montgomery \xE5sberg depression rating scale (madrs) total score"
      specifier: through phase 3
      measure: adjusted mean change
  185:
    partial: false
    structured:
    - object: duration of remission
      specifier: following cr (dor) in tp53 wt population
  186:
    partial: false
    structured:
    - object: resource utilization dementia-lite (rud - lite) scale
      time: week 104
      measure: change from baseline
  187:
    partial: false
    structured:
    - object: pharmacological interventions
      specifier: for the management of the cognitive impairment in the subgroups of
        the intervention arm with and without additional inputs from informants
      measure: number of participants
  188:
    partial: true
    structured:
    - object: am, pre-dose, instantaneous total nasal symptom (itnss) scores
      time: over the entire treatment period
      measure: mean change from baseline
  189:
    partial: false
    structured:
    - object: terminal elimination half life
  190:
    partial: false
    structured:
    - object: treatment-emergent adverse events (teaes)
      measure: number of participants
    - object: treatment-emergent serious adverse events (tesaes)
      measure: number of participants
  191:
    partial: false
    structured:
    - object: area under plasma concentration
  192:
    partial: false
    structured:
    - object: antibody response to mumps
      specifier: for subjects who had previously received m-m-r ii + varivax - geometric
        mean titer
  193:
    partial: false
    structured:
    - object: operator assessment
  194:
    partial: false
    structured:
    - object: electrocardiogram (ecg) values
      range: outside range of potential clinical importance
      measure: number of participants
  195:
    partial: false
    structured:
    - object: composite autonomic symptom score (compass)
  196:
    partial: false
    structured:
    - measure: percentage of patients
      object: crohn's disease activity index (cdai) response
      specifier: defined as a decrease of at least 100 points in cdai score from baseline
      time: at week 10
  197:
    partial: false
    structured:
    - measure: percentage of participants
      object: score for overall pelvic pain
      time: at week 52
      specifier: improvement, no change, or worsening from baseline
  198:
    partial: true
    structured:
    - measure: number of participants
      object: seropositive
      specifier: "within each treatment arm who achieved a a/h1n1 strain-specific\
        \ hai antibody titer \u2265 32 post dose"
  199:
    partial: false
    structured:
    - object: passed bladder trial
      measure: number of participants
  200:
    partial: false
    structured:
    - measure: cumulative percentage
      object: radioactive dose
      specifier: excreted in the urine
      unit: cum%dose
  201:
    partial: false
    structured:
    - measure: change
      object: site-level rates of weight monitoring
      time: at baseline
      specifier: within 30 days of a new antipsychotic prescription
  202:
    partial: false
    structured:
    - object: left ventricular ejection fraction
      specifier: assessed by cardiac magnetic resonance imaging (cmri)
  203:
    partial: false
    structured:
    - object: breast cancer-specific distress
      specifier: of the intrusive thoughts scale
  204:
    partial: false
    structured:
    - measure: geometric mean titers (gmts)
      object: serum antibodies
      specifier: to rsv
      time: at day 28 post dose 2
  205:
    partial: false
    structured:
    - measure: time to
      object: tumor response
      specifier: cr and pr
  206:
    partial: false
    structured:
    - object: nurse response time
  207:
    partial: false
    structured:
    - object: aecopd rate
      specifier: moderate with overall and specific viral pathogens in sputum
  208:
    partial: true
    structured:
    - measure: change from baseline
      object: alt
    - measure: change from baseline
      object: ast
    - measure: change from baseline
      object: alp
    - measure: change from baseline
      object: serum cpk
  209:
    partial: false
    structured:
    - measure: number of eyes
      object: corneal staining
      specifier: slit lamp findings
  210:
    partial: false
    structured:
    - measure: percentage of participants
      object: parkinson's disease symptoms
      range: improvement (cgi-i)
      specifier: clinical global impression
  211:
    partial: false
    structured:
    - object: patient enablement instrument
  212:
    partial: false
    structured:
    - measure: change from baseline
      object: severity of hematemesis
    - measure: change from baseline
      object: severity of melena gastrointestinal symptom
  213:
    partial: false
    structured:
    - measure: percentage
      object: tumor-specific t-cells
      specifier: correlation between immunological parameters and efficacy
  214:
    partial: true
    structured:
    - measure: number of subjects
      object: anti-rubella concentration
      range: greater than or equal to 4 iu/ml
  215:
    partial: false
    structured:
    - measure: assessment
      object: anti-tumor activity
      specifier: mri k-trans
      unit: 10^-3 / min
    - measure: assessment
      object: anti-tumor activity
      specifier: ceus
      unit: arbitrary units
    - object: pharmacokinetic profile
      measure: auc
      unit: ng*h/ml
  216:
    partial: false
    structured:
    - object: flu diagnosis
      specifier: among fellow household members
      range: high confidence
  217:
    partial: true
    structured:
    - object: quality of life
      specifier: assessed by the multiple sclerosis quality of life-54 (msqol-54)
        questionnaire
  218:
    partial: false
    structured:
    - measure: number of participants
      object: clinical cessation of status epilepticus
      specifier: intention to treat
  219:
    partial: true
    structured:
    #219,rate and extent of absorption of azd5718 by assessment of the half-life associated with terminal slope of a semi-logarithmic plasma concentration-time curve (t½λz) for part a - amorphous and crystalline suspension

    - measure: rate
      object: azd5718
      specifier: assessment of the half-life
  220:
    partial: false
    structured:
    - measure: percent change from baseline
      object: trabecular vbmd
      specifier: central section of spine
  221:
    partial: false
    structured:
    - object: dor
      specifier: as determined by the investigator using minrc in participants with
        neuroblastoma
  222:
    partial: false
    structured:
    - object: quality of life
      specifier: physical health composite
  223:
    partial: false
    structured:
    - measure: change
      object: evidence-based preventative care
  224:
    partial: false
    structured:
    - measure: change
      object: cognitive function
      specifier: pre-post changes functional assessment of cancer therapy-cognition
        [fact-cog]
  225:
    partial: false
    structured:
    - object: lipoprotein cholesterol
      specifier: high-density hdl-c
      unit: mmol/l
      time: during the study
  226:
    partial: false
    structured:
    - object: speed
      specifier: in the timed 25 feet walk test at self-selected speed (without exoskeleton)
  227:
    partial: false
    structured:
    - object: tumor response
      specifier: bone and soft tissue lesions
  228:
    partial: false
    structured:
    - measure: number of participants
      object: leakage observed
      specifier: during procedure
  229:
    partial: false
    structured:
    - measure: change from baseline
      object: simplified disease activity index (sdai)
      time: month 6
    - measure: change from baseline
      object: simplified disease activity index (sdai)
      time: month 12
  230:
    partial: false
    structured:
    - object: tumor response
      specifier: complete
  231:
    partial: false
    structured:
    - measure: mean change
      object: average pain severity
      specifier: by week by gabapentin exposure subgroup (de novo versus prior use)
      time: weekly in 24 hour average
  232:
    partial: false
    structured:
    - measure: percentage of participants
      object: physician's global assessment (pga) score
      specifier: of clear or minimal with at least a 2 grade reduction from baseline
      time: week 12
  233:
    partial: false
    structured:
    - measure: time to achieve
      object: das28(crp) lda
  234:
    partial: true
    structured:
    - object: pittsburg sleep quality index (psqi
      specifier: a commonly used and well-validated self-rated measure of sleep-quality
        and disturbance over 8-weeks
  235:
    partial: false
    structured:
    - object: minimum plasma concentration (cmin)
      specifier: 9-hydroxyrisperidone pk over the secondary peak
  236:
    partial: false
    structured:
    - measure: change from baseline
      object: self-monitored blood glucose (smbg)
      specifier: 7-point
  237:
    partial: false
    structured:
    - object: default network activity
  238:
    partial: false
    structured:
    - measure: number of subjects
      object: solicited systemic aes
    - measure: number of subjects
      object: other indicators
      specifier: reactogenicity
      time: after each vaccination
  239:
    partial: false
    structured:
    - object: overall survival
      time: phase iia
  240:
    partial: false
    structured:
    - measure: change
      object: activities of daily living inventory (adcs-adl)
      specifier: alzheimer's disease cooperative study
      time: from baseline to 104-week
  241:
    partial: false
    structured:
    - object: magnetic force
  242:
    partial: false
    structured:
    - object: stature-for-age z-score
      measure: absolute change
  243:
    partial: false
    structured:
    - measure: mean number
      object: biologic disease modifying antirheumatic drug (bdmard)
      time: received during variable length pre-index period
  244:
    partial: false
    structured:
    - measure: change
      object: sdnn
      unit: ms
  245:
    partial: true
    structured:
    - measure: change
      object: brain tumor interference score
      specifier: m. d. anderson symptom inventory (mdasi-bt)
  246:
    partial: false
    structured:
    - measure: number of participants
      object: clinical failure
      time: after initiation of radiotherapy
  247:
    partial: false
    structured:
    - measure: change from baseline
      object: number of binge days
  248:
    partial: false
    structured:
    - measure: number of participants
      object: intravitreal (ivt) aflibercept injections
      specifier: qualifying to receive
  249:
    partial: false
    structured:
    - measure: change from baseline
      object: basophils
      time: at day 7
    - measure: change from baseline
      object: eosinophils
      time: at day 7
    - measure: change from baseline
      object: lymphocytes
      time: at day 7
    - measure: change from baseline
      object: monocytes
      time: at day 7
    - measure: change from baseline
      object: total neutrophils
      time: at day 7
    - measure: change from baseline
      object: platelet count
      time: at day 7
    - measure: change from baseline
      object: white blood cell count
      time: at day 7
